Posts Archive

NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple...

MagnetisMM-3 NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma Relapsed & Refractory...

NCT04436029: Phase 2: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...

The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...

NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...

OPTIMAL-HiChemo NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma...

CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...

D-ClaPd NCT04302324: Phase 2: A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple...

NCT04445701: Phase 1/2: Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple...

NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission NCT04221178: Stopping Maintenance...

NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma This is a...

NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma Personalized Autologous Transplant for Multiple Myeloma...

(ITHACA) High-risk Smoldering Multiple Myeloma NCT04270409 NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and...

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...

Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...

CARTITUDE-4 Ciltacabtagene Autoleucel A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA),...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...

NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed...

MAMMOTH study Multicenter, retrospective study to investigate the natural history and outcomes of patients with MM refractory to CD38...